On a single page in the American Association for Cancer Research's newest report sits a startling number: 11 new cancer drugs cleared by U.S. regulators in just one year. That's not 11 over a decade — that's 11 between July 1, 2025, and June 30, 2026, a pace that describes a field racing forward faster than ever.
The group's annual Cancer Progress Report, led by Dr. Keith Flaherty of the AACR steering committee, isn't just a tally of victories. It's a snapshot of how cancer care is being rebuilt from the ground up. Among the newly approved treatments are three that would have been unthinkable not long ago. One is the first immune checkpoint inhibitor for ovarian cancer — a drug that helps the body's own defenses find and attack tumor cells. Another targets a rare, aggressive brain tumor that carries a specific genetic change. And in a first, patients with breast cancer now have access to a proteolysis-targeting chimera, a clever molecule that essentially marks harmful proteins for destruction inside cells.
The progress doesn't stop at new medicines. In the same year, the FDA approved new uses for five existing cancer treatments. It also cleared a wearable, noninvasive device designed to treat pancreatic cancer, one of the hardest cancers to catch early. And it gave the green light to artificial intelligence tools that help doctors spot and diagnose cancers sooner than ever before.
The report also points to what's next. Researchers are exploring weight-loss drugs called GLP-1 receptor agonists as a way to lower the risk of cancers linked to obesity. They're studying vaccines that might prevent cancer or treat it. And AI is being used not just to find tumors, but to speed up drug development and predict how well a patient will respond to treatment.
This matters because cancer remains one of the world's leading causes of death, and behind each approved therapy are years of painstaking research and the patients who make progress possible. Flaherty frames the moment as both a triumph and a call to action. "Progress against cancer is proceeding rapidly, with more breakthroughs on the horizon," he said. "We can't stop here."
His message to the scientific community is blunt: invest in research, share knowledge across laboratories, and train the next generation of cancer scientists. The more hands working on the problem, he argues, the faster discoveries turn into treatments that are precise, biology-driven, and life-changing.
The report is a reminder that hope in medicine is rarely a single breakthrough. More often, it's the steady accumulation of many — a new drug here, a new use there, a clever device, a smarter algorithm. Read together, they point in one direction: a future where cancer is caught earlier, treated more gently, and beaten more often.